This is a representative case study — a composite built on real industry benchmarks, not a single named client. The brands, timeline, and figures are illustrative, assembled from typical distribution economics and current US compliance requirements to show how onboarding a Korean portfolio actually works.
Taking on one Korean brand is a SKU decision. Taking on a portfolio of them is a different animal — it is a regulatory, logistics, and channel project that lives or dies on the work done before the first pallet lands. Here is how a US distributor onboards a three-brand Korean portfolio the right way, and where the predictable failures hide.
The setup
Picture a mid-size US beauty distributor with existing retail and spa accounts, deciding to add a curated Korean portfolio: a sheet-mask and skincare brand, a scalp-and-hair line, and a color/tone-up range. Three brands, roughly 40 active SKUs combined. The goal is not to dump 40 listings onto Amazon and hope. It is to build a defensible, compliant, multi-channel program. The work breaks into four phases.
Phase 1 — Curate and qualify (weeks 1–4)
The discipline here is subtraction. Of the 40 SKUs on offer, the distributor cuts to the ones that are both commercially live in the US and legally clean. That means flagging the traps early: anything making an SPF or “drug” claim routes into a separate, harder lane; anything with a US-restricted colorant or ingredient is parked; anything whose claims (anti-aging, “treats,” “heals”) would reclassify it as a drug gets its labeling rewritten or gets cut. A realistic first wave is 22–26 SKUs — the ones that can be on a shelf in 90 days without a compliance asterisk.
Phase 2 — Compliance onboarding (weeks 2–10, overlapping)
This is the phase amateurs skip and regret. Under MoCRA, selling cosmetics in the US now requires facility registration and product listing with the FDA, a named Responsible Person on each product, adverse-event recordkeeping, and substantiation for every claim. For an imported portfolio, the distributor typically becomes (or designates) the Responsible Person and owns that obligation for all three brands.
In parallel runs the unglamorous documentation work: ingredient (INCI) review against US-permitted lists, label conversion to US format (Drug Facts vs. cosmetic labeling, net contents, RP contact), and gathering manufacturing and safety files from each Korean factory. Budget real money and real weeks here — label and compliance onboarding across a multi-brand portfolio commonly runs into the low five figures and 6–10 weeks, because it moves at the speed of the slowest factory returning its paperwork.
Phase 3 — Logistics and landed cost (weeks 6–12)
With the SKU list locked, the distributor models the real landed cost — and 2025 made this phase heavier. Korean cosmetics that once entered near 0% duty now carry a tariff in the mid-teens, and the $800 de minimis exemption is gone, so the old small-parcel shortcut is dead. The right structure is consolidation: one ocean freight program across all three brands, correct HTS classification per SKU, documented country of origin, and a bonded or properly-entered inventory position in a US warehouse. Done well, consolidation absorbs much of the tariff shock that would crush a parcel-by-parcel model.
Phase 4 — Channel and pricing (weeks 8–16)
Now the portfolio goes to market, and the channels are sequenced, not simultaneous:
- Pro / spa first. Existing spa and salon accounts take the scalp line and treatment skincare at professional margins, with protocol support — fast revenue, no marketplace price war.
- Amazon as the demand engine. The hero SKUs from each brand seed marketplace presence and reviews, with controlled pricing to protect the retail accounts.
- Retail / boutique last, once reviews and reorder data prove the velocity a buyer wants to see.
On economics, the standard model holds: the distributor buys at roughly 50–55% off the US retail price, sells to retail accounts near keystone, and protects 30–40 points after tariff and freight — provided the landed cost in Phase 3 was modeled honestly. A full first wave from signed agreement to live-on-shelf realistically takes four to five months, with compliance, not logistics, as the long pole.
Where portfolio onboarding goes wrong
The failures rhyme. A distributor lists all 40 SKUs to “see what sells,” including three that make drug claims, and inherits a compliance problem on day one. They treat MoCRA as a checkbox and discover the Responsible Person obligation only when something goes wrong. They model landed cost on last year’s duty-free assumption and find the tariff in their margin instead of their plan. Or they launch everything on Amazon at once, blow up their own retail pricing, and lose the wholesale accounts that were supposed to be the stable base. Every one of these is a planning failure, not a market failure.
The operator’s view
A Korean portfolio is more valuable than the sum of its brands — one freight lane, one compliance apparatus, one Responsible Person, one warehouse position spread across 25 SKUs — but only if it is onboarded as a system. The distributors who win are the ones who do the subtraction, the registration, and the landed-cost modeling before the inventory ships, so the launch is the easy part.
How Luxmetics supports this is end to end: we curate and qualify the SKU list against US rules, stand up the MoCRA and labeling compliance, model and consolidate the landed cost under the current tariff regime, and sequence the channel rollout so the marketplace does not cannibalize the retail accounts. The portfolio is the opportunity. The onboarding is where it is won or lost.